Cargando…
Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672367/ https://www.ncbi.nlm.nih.gov/pubmed/36405303 http://dx.doi.org/10.1016/j.euros.2022.09.022 |
| _version_ | 1784832717128466432 |
|---|---|
| author | Gómez Rivas, Juan Gandaglia, Giorgio Montorsi, Francesco |
| author_facet | Gómez Rivas, Juan Gandaglia, Giorgio Montorsi, Francesco |
| author_sort | Gómez Rivas, Juan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9672367 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96723672022-11-19 Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice Gómez Rivas, Juan Gandaglia, Giorgio Montorsi, Francesco Eur Urol Open Sci Letter to the Editor Elsevier 2022-11-14 /pmc/articles/PMC9672367/ /pubmed/36405303 http://dx.doi.org/10.1016/j.euros.2022.09.022 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Letter to the Editor Gómez Rivas, Juan Gandaglia, Giorgio Montorsi, Francesco Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice |
| title | Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice |
| title_full | Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice |
| title_fullStr | Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice |
| title_full_unstemmed | Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice |
| title_short | Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice |
| title_sort | re: neal d. shore, joseph renzulli, neil e. fleshner, et al. active surveillance plus enzalutamide monotherapy vs active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer: the enact randomized clinical trial. jama oncol 2022;8:1128–36: let’s not go back in time! what have we learned in the treatment of localized prostate cancer? applicability of the enact randomized clinical trial in clinical practice |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672367/ https://www.ncbi.nlm.nih.gov/pubmed/36405303 http://dx.doi.org/10.1016/j.euros.2022.09.022 |
| work_keys_str_mv | AT gomezrivasjuan renealdshorejosephrenzullineilefleshneretalactivesurveillanceplusenzalutamidemonotherapyvsactivesurveillancealoneinpatientswithlowriskorintermediaterisklocalizedprostatecancertheenactrandomizedclinicaltrialjamaoncol20228112836letsnotgobackintimewhathavewe AT gandagliagiorgio renealdshorejosephrenzullineilefleshneretalactivesurveillanceplusenzalutamidemonotherapyvsactivesurveillancealoneinpatientswithlowriskorintermediaterisklocalizedprostatecancertheenactrandomizedclinicaltrialjamaoncol20228112836letsnotgobackintimewhathavewe AT montorsifrancesco renealdshorejosephrenzullineilefleshneretalactivesurveillanceplusenzalutamidemonotherapyvsactivesurveillancealoneinpatientswithlowriskorintermediaterisklocalizedprostatecancertheenactrandomizedclinicaltrialjamaoncol20228112836letsnotgobackintimewhathavewe |